Your browser doesn't support javascript.
loading
Carfilzomib, daratumumab, and dexamethasone (KdD) vs. lenalidomide-sparing pomalidomide-containing triplet regimens for relapsed/refractory multiple myeloma: an indirect treatment comparison.
Weisel, Katja; Dimopoulos, Meletios A; Beksac, Meral; Leleu, Xavier; Richter, Joshua; Heeg, Bart; Patel, Sachin; Majer, Istvan; McFadden, Ian; Mikhael, Joseph.
Afiliação
  • Weisel K; Department of Oncology, Hematology and Bone Marrow Transplantation with Section of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Dimopoulos MA; Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece.
  • Beksac M; Ankara University, Ankara, Turkey.
  • Leleu X; CHU de Poitiers - La Miletrie, INSERM CIC 1402, Poitiers, France.
  • Richter J; Tisch Cancer Institute, Mount Sinai School of Medicine, New York, NY, USA.
  • Heeg B; Cytel Inc, Rotterdam, The Netherlands.
  • Patel S; Amgen Ltd, Uxbridge, UK.
  • Majer I; Amgen (Europe) GmbH, Rotkreuz, Switzerland.
  • McFadden I; Amgen Inc, Thousand Oaks, CA, USA.
  • Mikhael J; Translational Genomics Research Institute (TGen), City of Hope Cancer Center, Phoenix, AZ, USA.
Leuk Lymphoma ; 65(4): 481-492, 2024 Apr.
Article em En | MEDLINE | ID: mdl-38345269
ABSTRACT
Nearly all patients with multiple myeloma eventually relapse or become refractory to treatment. Lenalidomide is increasingly administered in the frontline until disease progression or intolerance to therapy, resulting in the need for highly effective, lenalidomide-sparing options. In this study, carfilzomib plus daratumumab and dexamethasone were evaluated against lenalidomide-sparing, pomalidomide-containing triplets using matching-adjusted indirect comparison in the absence of head-to-head data. The analyses utilized long-term follow-up data from the CANDOR study (NCT03158688). Treatment with carfilzomib, daratumumab, and dexamethasone resulted in significantly longer progression-free survival (hazard ratio 0.60 [95% confidence interval 0.37, 0.88])vs. pomalidomide plus bortezomib and dexamethasone, and numerically longer progression-free survival (hazard ratio 0.77 [95% confidence interval 0.50, 1.08]) vs. daratumumab plus pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma and previous lenalidomide exposure, the majority of whom were lenalidomide refractory. Carfilzomib plus daratumumab and dexamethasone offers a highly effective, lenalidomide-sparing treatment option for this population.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Oligopeptídeos / Talidomida / Anticorpos Monoclonais / Mieloma Múltiplo Limite: Humans Idioma: En Revista: Leuk Lymphoma Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Oligopeptídeos / Talidomida / Anticorpos Monoclonais / Mieloma Múltiplo Limite: Humans Idioma: En Revista: Leuk Lymphoma Ano de publicação: 2024 Tipo de documento: Article